Canada Breast Cancer Diagnostics Market Insights Forecasts to 2033
- The Market Size is Growing at a Substantial CAGR from 2023 to 2033.
- The Canada Breast Cancer Diagnostics Market Size Expected to Hold a Significant Share by 2033.
Get more details on this report -
The Canada Breast Cancer Diagnostics Market size is expected to hold a significant Share by 2033, at a Substantial CAGR during the forecast period 2023 to 2033.
Breast cancer is defined as a malignant tumor that develops in breast cells and has the potential to spread to other parts of the body. Women are more likely than men to develop breast cancer. When diagnosing breast cancer, doctors use a variety of tests to determine where the tumor started and how far it has spread throughout the body. Breast cancer symptoms include a lump in the breast, changes in the breast's shape, skin dimpling, fluid leakage from the nipple, patches of discolored skin, and so on. Breast cancer can develop in healthy people owing to a variety of risk factors, including alcohol consumption, obesity, menopause, family history, and having children later in life. This is owing to the rising incidence of breast cancer and advances in imaging technology, such as 3-D mammography, which improves early detection and screening capabilities. Furthermore, the availability of highly effective medications has led to an increase in demand for various diagnostic tests such as mammograms, breast magnetic resonance imaging, and biopsies. Demand for advanced mammography devices will also drive the lucrative growth of the Canadian breast cancer diagnostics market.
This research report categorizes the market for Canada Breast Cancer Diagnostics Market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Canada breast cancer diagnostics market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Canada breast cancer diagnostics market.
Canada Breast Cancer Diagnostics Market Report Coverage
|2023 - 2033
|Historical Data for:
|2019 - 2022
|No. of Pages:
|Tables, Charts & Figures:
|By Type, By Application, By End-use, and COVID-19 Impact Analysis.
|Philips Canada Ltd, Danaher Corp, Hologic Inc, Becton Dickinson Canada Inc, Thermo Fisher Scientific Inc, Genomic Health Inc, Argon Medical Devices Inc, Hoffmann-La Roche Ltd, and Others
|Pitfalls & Challenges:
|COVID-19 Empact, Challenge, Future, Growth, & Analysis
Get more details on this report -
Technological advancements have had an enormous effect on the growth of the Canada breast cancer diagnostics market, as advanced imaging modalities allow healthcare professionals to detect tumors at smaller sizes and earlier stages, leading to more effective treatment outcomes. As a consequence, the demand for therapeutics targeting early-stage breast cancer rises, driving market growth. Furthermore, the implementation of precision medicine strategies promotes the development of targeted therapies, which drives market growth. The availability of targeted therapies and immunotherapies broadens treatment options, improves patient outcomes, and drives market growth. As a result, technology enables healthcare providers to monitor patients remotely, conduct virtual consultations, and provide supportive care services. Remote monitoring and telemedicine allow for timely interventions, reducing the burden on healthcare systems and improving patient access to care. The use of these technologies in breast cancer care promotes market growth and improves patient outcomes.
The high cost of cancer diagnostic treatments and a shortage of skilled professionals hamper market growth. Furthermore, one of the most significant obstacles is unequal access to breast cancer diagnostics. Disparities in healthcare access, particularly in low-income and underserved areas, can limit the availability of diagnostic services. Also, an issue with breast cancer diagnostics is the possibility of overdiagnosis and false positives. Overly sensitive diagnostic tools can result in unnecessary treatments, causing physical and emotional distress to patients. Finding the right balance of sensitivity and specificity is a difficult task.
- In 2023, the imaging segment accounted for the largest revenue share over the forecast period.
Based on type, the Canada breast cancer diagnostics market is segmented into imaging, biopsy, genomic tests, blood tests, and others. Among these, the imaging segment has the largest revenue share over the forecast period. This is primarily due to the widespread use of imaging techniques such as mammography, ultrasound, and MRI. These techniques have become the primary means of diagnosing breast cancer, while cutting-edge technologies such as MBI, CT, 3D breast tomosynthesis, and PET show promise for revolutionizing breast imaging capabilities.
- In 2023, the diagnostic and predictive segment is witnessing the largest growth over the forecast period.
Based on application, the Canada breast cancer diagnostics market is segmented into screening, diagnostic and predictive, prognostic, research, and others. Among these, the diagnostic and predictive are witnessing the largest growth over the forecast period. Breast cancer diagnostics include a variety of tests, including biopsies, MRI, CT scans, and PET scans, to confirm the presence of the disease and assess tumor characteristics. These tests are critical for guiding treatment decisions and gathering disease-related information. As the breast cancer diagnostic market becomes more competitive, there is an increased emphasis on predictive diagnosis.
- In 2023, the hospitals & clinics segment is witnessing largest growth over the forecast period.
Based on end use, the Canada breast cancer diagnostics market is segmented into hospitals & clinics, diagnostic centers and medical laboratories, and others. Among these, the hospitals & clinics segment is witnessing the largest growth over the forecast period. Rising patient hospitalizations and an increasing disease burden are expected to drive the segmental growth. After the screening test, individuals undergo biopsies at hospitals for confirmation testing. The diagnostic centers and medical laboratories sector are projected to expand the largest growth in the forecast period owing to an increase in the number of government programs offering various services, such as diagnostic test reimbursement.
The report offers the appropriate analysis of the key organizations/companies involved within the Canada breast cancer diagnostics market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Philips Canada Ltd
- Danaher Corp
- Hologic Inc
- Becton Dickinson Canada Inc
- Thermo Fisher Scientific Inc
- Genomic Health Inc
- Argon Medical Devices Inc
- Hoffmann-La Roche Ltd
Key Target Audience
- Market Players
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
This study forecasts revenue at regional, and country levels from 2022 to 2033. Spherical Insights has segmented the Canada breast cancer diagnostics market based on the below-mentioned segments:
Canada Breast Cancer Diagnostics Market, By Type
- Genomic Tests
- Blood Tests
Canada Breast Cancer Diagnostics Market, By Application
- Diagnostic and Predictive
Canada Breast Cancer Diagnostics Market, By End-use
- Hospitals & Clinics
- Diagnostic Centers and Medical Laboratories
Need help to buy this report?